Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience

Dhand, Abhay; Lobo, Stephen; Wolfe, Kevin; Feola, Nicholas; Lee, Leslie; Nog, Rajat; Chen, Donald; Glicklich, Daniel; Diflo, Thomas; Nabors, Christopher

doi:10.1097/tp.0000000000003737

Cited by 50 publications

(53 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dhand et al reported encouraging results in SOT patients given bamlanivimab monotherapy or casirivimab/imdevimab without a control group. 4 , 5 Herein, we compared the outcome of SOT patients who were given monoclonal antibodies to an historical control group. According to French law (Loi Jardé), anonymous retrospective studies do not require Institutional Review Board approval.…”

Section: To the Editormentioning

confidence: 99%

Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients

et al. 2021

View full text Add to dashboard Cite

Solid-organ transplant (SOT) patients are at high risk of developing severe coronavirus disease-19 . Neutralizing monoclonal antibodies that bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein prevent viral attachment to ACE2 receptor. When administered to immunocompetent patients in the early phase of infection, they reduce the risk of hospitalization and improved symptoms resolution. 1,2 Similar data were reported in a real-life study that included 69 immunosuppressed patients. 3 However, the proportion of SOT patients and their specific outcome were not reported. Dhand et al reported encouraging results in SOT patients given bamlanivimab monotherapy or casirivimab/imdevimab without a control group. 4,5 Herein, we compared the outcome of SOT patients who were given monoclonal antibodies to an historical control group. According to French law (Loi Jardé), anonymous retrospective studies do not require Institutional Review Board approval. In France, the use of monoclonal antibodies was approved on February 25, 2021 for immunosuppressed patients with positive SARS-CoV-2 nasopharyngeal RT-PCR, having symptoms

show abstract

Section: To the Editormentioning

confidence: 99%

Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Dhand et al reported promising results in 25 solid organ transplant (SOT) patients treated with REIGN-COV2. After a median of 41days of follow up, none of the patients treated with the cocktail was hospitalized dot to COVID-19 [17] .…”

Section: Resultsmentioning

confidence: 99%

“…Clinically, the combination of casirivimab and imdevimab or bamlanivimab and etesevimab reduced the hospitalization rate and emergency department admissions in patients with a mild infection, and risk factors for severe manifestation from COVID-19 [23] , [81] ( Figure 1 , Figure 2 ). [17] , [22] Following these results, the FDA and EMA released a EUA for both the combination of casirivimab and imdevimab and bamlanivimab and etesevimab for mild symptomatic adults with COVID-19 who are not in need of additional oxygen but are at high risk of becoming severely ill. However, monoclonal antibodies are expected to work better in the early infective phase of SARS-CoV2 infection, whereas the late phases are driven by immune dysregulation responsible to severe manifestation in critical patients [82] , [83] .…”

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?

Pinna

Lupia

Scabini

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

The world is facing up the most considerable vaccination effort in history to end the Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) direct against the Receptor binding domain of the S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) received an Emergency Use Authorization for outpatient management of mild to moderate manifestation from COVID-19. MAbs could prevent the transmission SARS-CoV-2 infection and protect individuals from progression to severe disease. Under the pressure of different treatment strategies, SARS-CoV-2 has been demonstrated to select for different sets of mutations named “variants” that could impair the effectiveness of mAbs by modifying target epitopes. We provide an overview of both completed and unpublished, or ongoing clinical trials of mAbs used and review state of art in order to describe clinical options, possible indications, and the place in therapy for these agents in the treatment of COVID-19 with a particular focus on anti-spike agents. Then, we reassume the current evidence on mutations of the SARS-CoV-2 that might confer resistance to neutralization by multiple mAbs.

show abstract

“…Regarding therapeutics, the partnership rapidly initiated clinical trials of a repurposed antiviral, remdesivir, that was subsequently shown to be of value in treating patients infected with SARS-CoV-2. 4,5 Working with pharma, Operation Warp Speed also fostered the development of monoclonal antibodies directed against the SARS-CoV-2 spike protein [6][7][8] and encouraged the collection of convalescent plasma, both of which were demonstrated to be of value in the treatment of early COVID-19 infection but of less value in severely ill patients with the disease. 9 In addition, Operation Warp Speed fostered studies of drugs intended to abrogate the cytokine storm associated with severe COVID-19 infection, including interlekin-6 receptor blockers, such as tocilizumab and sarilumab, and Janus kinase inhibitors, such as baracitinib and tofacitinib, though the precise roles for these compounds in the therapy of COVID-19 remains somewhat controversial.…”

Section: What Went Well In the Pandemic Response?mentioning

confidence: 99%